Quick Dispatch:
Your cvot tirzepatide SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your cvot tirzepatide SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic ships.
Need Help?
Questions about cvot tirzepatide SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for cvot tirzepatide SURPASS-CVOT trial results: Tirzepatide's impact on diabetes and cardiovascular disease | Paramesh Shamanna posted on the topic in your area.
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx
20.96
Frontiers
28.46
Diabetes Distilled: SURPASS-CVOT – Tirzepatide demonstrates cardiovascular benefit in secondary prevention
23.48
💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What
23.08
Tirzepatide demonstrates cardiovascular protection in head-to-head trial with dulaglutide
29.40
Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and
25.29
Frontiers
27.67
